← Back to Clinical Trials
Recruiting NCT06923423

NCT06923423 Effectiveness, Implementation, and Cost of Cognitive Processing Therapy in Prisons

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06923423
Status Recruiting
Phase
Sponsor University of Arkansas
Condition PTSD - Post Traumatic Stress Disorder
Study Type INTERVENTIONAL
Enrollment 640 participants
Start Date 2025-07-07
Primary Completion 2028-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Group Cognitive Processing Therapy (CPT)Control Group Individual trauma focused self-help via workbook

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 640 participants in total. It began in 2025-07-07 with a primary completion date of 2028-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Addiction and trauma exposure are common among the 5.5 million people (1 in 47 adults) in the U.S. who are in prison or under supervision. About 85% of people in prison have a substance use disorder or are there for a drug-related crime, and many have experienced serious trauma before being incarcerated. Posttraumatic stress symptoms (PTSS) are often a result of trauma and are linked to more severe drug use, higher rates of relapse, and increased crime. PTSS and substance use disorder (SUD) each raise the chances of new arrests for people who are justice-involved, showing that addressing trauma and addiction could help reduce repeat offenses and the costs of incarceration. However, treatments for PTSS are rarely available in prisons, and there is little research on whether providing therapy for PTSS in prison can lower drug use, PTSS, or crime after release. The goal of this clinical trial is to see if trauma-focused group therapy (CPT) provided while in prison, can help people after release from prison. The therapy has been adapted for use in prisons (CPT-CJ) and will be compared to trauma focused therapy delivered via a self-help workbook This study will: * test whether a trauma-focused group therapy (CPT-CJ) can reduce post-incarceration drug and alcohol use, mental health issues, and drug-related crime, compared to trauma-focused self-help, * evaluate a strategy called implementation facilitation, which helps support the use of this therapy in prisons, and * measure the cost of the therapies and support strategies to help plan for future expansion. Incarcerated participants (N = 640; 50% female) will be enrolled from \~10 prisons in \~5 states, ensuring variability in population and setting characteristics. They will: * take surveys and answer questions up to 5 times (before starting treatment, right after getting treatment, right before leaving prison, 3 months after leaving prison and 6 months after leaving prison) * complete CPT group therapy or self-help therapy * provide urine samples 3 months and 6 months after leaving prison Prison stakeholders (e.g., prison staff, prison leadership, governmental officials; N = \~15 per site) who will be purposively sampled based on their role in CPT-CJ implementation will also participate in some surveys.

Eligibility Criteria

Inclusion Criteria: * 18 years of age or older * Able to understand and speak English * Able to give informed consent * All items listed in "Inclusion criteria for all participants" * Be currently incarcerated in one of the prisons that have partnered as study sites * Have met criteria for a drug use disorder in the year prior to their current incarceration (≥ 2 symptoms on a DSM-5 drug use disorder checklist) * Have used drugs in the 30 days prior to their current incarceration * Have a history of traumatic event exposure * Endorse clinically significant posttraumatic stress symptoms (score ≥ 4 on the Primary Care PTSD Screen for DSM-5; PC-PTSD-5) * Expect to be incarcerated for at least long enough to complete CPT-CJ as it is being implemented at the particular site (i.e., anticipated to be \~3 months, but will depend on dates associated with next available intervention group) * Expect to be released from prison within 12 months following the end of treatment (i.e., within \~15 months of the pre-treatment assessment) * Willing to consent to randomization to treatment condition Exclusion criteria for prisoners (additional requirements assessed during pre-treatment assessments or indicated by prison staff; will result in being withdrawn from the study prior to randomization by the PI): * Unable to provide any locator information for post-release assessments * Determined to be releasing sooner than would allow the individual to complete CPT-CJ * Determined to have an unavoidable scheduling conflict or facility restriction (e.g., disciplinary, medical) that would prevent participation in CPT-CJ. Of note, if the scheduling conflict or facility restriction is expected to resolve following the next round of randomization at the study site, the participant may be put on "hold for next round" status rather than withdrawn unless other exclusionary criteria would be met by that time (e.g., release).

Contact & Investigator

Central Contact

Melissa J Zielinski, PhD

✉ MJZielinski@uams.edu

📞 501-526-8229

Principal Investigator

Melissa J Zielinski, PhD

PRINCIPAL INVESTIGATOR

University of Arkansas

Frequently Asked Questions

Who can join the NCT06923423 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying PTSD - Post Traumatic Stress Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06923423 currently recruiting?

Yes, NCT06923423 is actively recruiting participants. Contact the research team at MJZielinski@uams.edu for enrollment information.

Where is the NCT06923423 trial being conducted?

This trial is being conducted at Little Rock, United States, Osceola, United States, Texarkana, United States, West Memphis, United States and 2 additional locations.

Who is sponsoring the NCT06923423 clinical trial?

NCT06923423 is sponsored by University of Arkansas. The principal investigator is Melissa J Zielinski, PhD at University of Arkansas. The trial plans to enroll 640 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology